JPMorgan Chase & Co. Initiates Coverage on Septerna (NASDAQ:SEPN)

JPMorgan Chase & Co. started coverage on shares of Septerna (NASDAQ:SEPN) in a report released on Tuesday, Marketbeat.com reports. The brokerage issued an overweight rating and a $38.00 price target on the stock.

A number of other research firms also recently issued reports on SEPN. Cantor Fitzgerald assumed coverage on shares of Septerna in a research note on Tuesday. They set an “overweight” rating and a $50.00 price objective on the stock. Wells Fargo & Company began coverage on Septerna in a research note on Tuesday. They issued an “overweight” rating and a $43.00 target price for the company. Finally, TD Cowen assumed coverage on shares of Septerna in a report on Tuesday. They issued a “buy” rating on the stock.

Septerna Stock Performance

Septerna stock opened at $22.00 on Tuesday. Septerna has a 1 year low of $18.62 and a 1 year high of $26.34.

Insider Transactions at Septerna

In other Septerna news, major shareholder Rock Ventures V. L.P. Third bought 370,500 shares of the stock in a transaction on Monday, October 28th. The shares were bought at an average price of $18.00 per share, with a total value of $6,669,000.00. Following the purchase, the insider now directly owns 6,215,591 shares in the company, valued at $111,880,638. This trade represents a 6.34 % increase in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink.

About Septerna

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases.